サンプル依頼リスト カート
  • English
  • Korean
デフォルト表紙
市場調査レポート
商品コード
1660919

低分子CMO/CDMOの世界市場：業界分析、規模、シェア、成長、動向、予測（2025年～2032年）

Small Molecule CMO/CDMO Market: Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2025 - 2032

出版日
ページ情報
英文 184 Pages
納期
2～5営業日
カスタマイズ可能
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=144.06円
低分子CMO/CDMOの世界市場：業界分析、規模、シェア、成長、動向、予測（2025年～2032年）
出版日: 2025年02月18日
発行: Persistence Market Research
ページ情報: 英文 184 Pages
納期: 2～5営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

世界の低分子CMO/CDMOの市場規模は、2025年に792億8,000万米ドルになるとみられ、2025年～2032年の予測期間に5.3%のCAGRで拡大し、2032年には1,141億7,000万米ドルに達すると予測されています。

低分子CMO/CDMO市場には、医薬品低分子の製造受託および市場開拓受託サービスが幅広く含まれます。これらのサービスは製薬企業やバイオテクノロジー企業に対応するよう設計されており、医薬品開発、製剤化、製造、包装のためのエンドツーエンドのソリューションを提供します。市場は、大手製薬会社、新興バイオテクノロジー企業、ジェネリック医薬品メーカーなど、さまざまなセグメントにサービスを提供しています。成長の原動力は、アウトソーシングの動向、コスト効率の向上、医薬品の製剤化・製造における専門的知識に対する需要の高まりです。

世界の低分子CMO/CDMO市場を牽引している主な要因はいくつかあります。コストメリットと業務効率の高さから、医薬品製造工程のアウトソーシング需要が高まっていることが、市場成長の原動力となっています。また、医薬品承認数の増加と低分子医薬品の複雑化により、製薬企業は専門的な製造パートナーを求めるようになっています。連続製造や高力価原薬（HPAPI）製造などの高度な製造技術の統合が、市場拡大をさらに後押ししています。さらに、規制への対応や適正製造基準（GMP）の専門知識の必要性が、専門的なCMO/CDMOとの提携を企業に促しています。

市場は、がんや中枢神経系（CNS）疾患など、高価値かつニッチな治療用途への需要の高まりに牽引され、大きな機会をもたらしています。高活性医薬品成分（HPAPI）や、ナノ粉砕や噴霧乾燥などの特殊な製剤技術における能力の拡大は、有利な成長の可能性をもたらします。新興市場、特にアジア太平洋は、運営コストの低下と良好な規制環境により、CMO/CDMOにとって大きな機会となっています。さらに、受託製造プロセスにおけるデジタルトランスフォーメーションと自動化の進展が効率性と拡張性を向上させ、市場成長をさらに促進しています。

当レポートでは、世界の低分子CMO/CDMO市場について調査し、製品別、サービス別、企業規模別、運用規模別、地域別動向、および市場に参入する企業のプロファイルなどを提供しています。

目次

第1章 エグゼクティブサマリー

第2章 市場概要

  • 市場の範囲と定義
  • 市場力学
  • マクロ経済要因
  • COVID-19の影響分析
  • 予測要因- 関連性と影響

第3章 付加価値の洞察

第4章 世界の低分子CMO/CDMO市場の見通し

  • 主なハイライト
  • 市場規模（10億米ドル）分析と予測
  • 世界の低分子CMO/CDMO市場の見通し：製品別
  • 世界の低分子CMO/CDMO市場の見通し：サービス別
  • 世界の低分子CMO/CDMO市場の見通し：企業規模別
  • 世界の低分子CMO/CDMO市場の見通し：運用規模別

第5章 世界の低分子CMO/CDMO市場の見通し：地域別

  • 主なハイライト
  • 過去の市場規模（10億米ドル）分析、地域別、2019年～2024年
  • 現在の市場規模（10億米ドル）の分析と予測、地域別、2025年～2032年
  • 市場の魅力分析：地域別

第6章 北米の低分子CMO/CDMO市場の見通し

第7章 欧州の低分子CMO/CDMO市場の見通し

第8章 東アジアの低分子CMO/CDMO市場の見通し

第9章 南アジアおよびオセアニアの低分子CMO/CDMO市場の見通し

第10章 ラテンアメリカの低分子CMO/CDMO市場の見通し

第11章 中東・アフリカの低分子CMO/CDMO市場の見通し

第12章 競合情勢

  • 市場シェア分析、2024年
  • 市場構造
  • 企業プロファイル（詳細- 概要、財務、戦略、最近の動向）
    • Lonza
    • Pfizer CentreOne (Pfizer Inc.)
    • Piramal Pharma Solutions
    • Wuxi App Tec
    • Patheon (Thermo Fisher Scientific Inc.)
    • Ajinomoto Bio-Pharma Solutions
    • Siegfried Holding AG
    • Eurofins Scientific
    • Aurigene Pharmaceutical Services Ltd.
    • Asymchema
    • PCI Pharma Services
    • Almac Group
    • Labcorp Drug Development
    • Sumitomo Chemical Co., Ltd.
    • ICROM
    • AGC Inc.
    • FUJIFILM Corporation
    • CMIC HOLDINGS Co., LTD.
    • Evonik
    • Terumo Pharmaceutical Solutions

第13章 付録

目次
Product Code: PMRREP33803

Persistence Market Research has recently published an extensive report on the global Small Molecule CMO/CDMO Market. This report offers a comprehensive analysis of the key market dynamics, including drivers, trends, opportunities, and challenges, providing deep insights into the market structure.

Key Insights:

  • Small Molecule CMO/CDMO Market Size (2025E): USD 79.28 Bn
  • Projected Market Value (2032F): USD 114.17 Bn
  • Global Market Growth Rate (CAGR 2025 to 2032): 5.3%

Small Molecule CMO/CDMO Market - Report Scope:

The Small Molecule CMO/CDMO Market encompasses a broad range of contract manufacturing and contract development services for pharmaceutical small molecules. These services are designed to cater to pharmaceutical and biotechnology companies, providing end-to-end solutions for drug development, formulation, production, and packaging. The market serves various segments, including large pharmaceutical firms, emerging biotech companies, and generic drug manufacturers. Growth is driven by increasing outsourcing trends, cost-efficiency, and the rising demand for specialized expertise in drug formulation and production.

Market Growth Drivers:

Several key factors are driving the global Small Molecule CMO/CDMO Market. The rising demand for outsourcing pharmaceutical manufacturing processes due to cost advantages and operational efficiencies is fueling market growth. Additionally, the increasing number of drug approvals and the growing complexity of small molecule drugs have led pharmaceutical companies to seek specialized manufacturing partners. The integration of advanced manufacturing technologies such as continuous manufacturing and high-potency API (HPAPI) production is further supporting market expansion. Furthermore, regulatory compliance and the need for expertise in Good Manufacturing Practices (GMP) are encouraging companies to collaborate with specialized CMO/CDMOs.

Market Restraints:

Despite promising growth prospects, the Small Molecule CMO/CDMO Market faces challenges related to stringent regulatory requirements and intellectual property concerns. The complex approval processes for contract manufacturers, including compliance with the U.S. FDA, EMA, and other regulatory agencies, can delay production timelines. Additionally, pharmaceutical companies often face concerns about the security of proprietary formulations and technologies when outsourcing to third parties. Market growth can also be hindered by capacity constraints at contract manufacturing facilities and the high costs associated with advanced technological capabilities.

Market Opportunities:

The market presents significant opportunities driven by the increasing demand for high-value and niche therapeutic applications, including oncology and central nervous system (CNS) disorders. The expansion of capabilities in high-potency active pharmaceutical ingredients (HPAPIs) and specialized formulation techniques, such as nano-milling and spray drying, provides lucrative growth potential. Emerging markets, particularly in Asia-Pacific, present significant opportunities for CMO/CDMOs due to lower operational costs and favorable regulatory environments. Additionally, advancements in digital transformation and automation in contract manufacturing processes are improving efficiency and scalability, further driving market growth.

Key Questions Answered in the Report:

  • What are the primary factors driving the growth of the Small Molecule CMO/CDMO Market globally?
  • Which contract manufacturing and development services are in high demand across pharmaceutical companies?
  • How are technological advancements influencing the competitive landscape of the Small Molecule CMO/CDMO Market?
  • Who are the key players in the Small Molecule CMO/CDMO Market, and what strategies are they employing to stay competitive?
  • What are the emerging trends and future prospects in the global Small Molecule CMO/CDMO Market?

Competitive Intelligence and Business Strategy:

Leading players in the global Small Molecule CMO/CDMO Market, including Lonza Group, Catalent Inc., and WuXi AppTec, focus on innovation, capacity expansion, and strategic collaborations to gain a competitive edge. These companies invest in R&D to enhance contract development and manufacturing capabilities while expanding their service portfolios. Collaborations with pharmaceutical firms, biotech startups, and government agencies facilitate market access and support long-term growth. Emphasis on regulatory compliance, high-quality manufacturing standards, and robust marketing strategies fosters market expansion and strengthens brand reputation in the evolving Small Molecule CMO/CDMO Market landscape.

Key Companies Profiled:

  • Lonza
  • Pfizer CentreOne (Pfizer Inc.)
  • Piramal Pharma Solutions
  • Wuxi App Tec
  • Patheon (Thermo Fisher Scientific Inc.)
  • Ajinomoto Bio-Pharma Solutions
  • Siegfried Holding AG
  • Eurofins Scientific
  • Aurigene Pharmaceutical Services Ltd.
  • Asymchema
  • PCI Pharma Services
  • Almac Group
  • Labcorp Drug Development
  • Sumitomo Chemical Co., Ltd.
  • ICROM
  • AGC Inc.
  • FUJIFILM Corporation
  • CMIC HOLDINGS Co., LTD.
  • Evonik
  • Terumo Pharmaceutical Solutions (TPS)

Small Molecule CMO/CDMO Market Segmentation

By Product

  • Standard API
  • HP API

By Service

  • Process Development
  • Analytical Method Development
  • GMP Manufacturing Service
  • Scale-up and Tech Transfer
  • Regulatory Assistance
  • Fill-finish Services

By Company Size

  • Small
  • Mid-sized
  • Large

By Scale of Operation

  • Clinical
  • Commercial

By Region

  • North America
  • Europe
  • East Asia
  • South Asia and Oceania
  • Middle East and Africa
  • Latin America

Table of Contents

1. Executive Summary

  • 1.1. Global Small Molecule CMO/CDMO Market Outlook
  • 1.2. Global Small Molecule CMO/CDMO Market Outlook: Services
  • 1.3. Introduction/Key Findings
  • 1.4. Historical Market Size (US$ Bn) and Analysis, By Services, 2019 - 2024
  • 1.5. Current Market Size (US$ Bn) and Analysis and Forecast, By Services, 2025 - 2032
  • 1.6. Key Market Trends
  • 1.7. Future Market Projections
  • 1.8. Premium Market Insights
  • 1.9. Industry Developments and Key Market Events
  • 1.10. PMR Analysis and Recommendations

2. Market Overview

  • 2.1. Market Scope and Definition
  • 2.2. Market Dynamics
    • 2.2.1. Drivers
    • 2.2.2. Restraints
    • 2.2.3. Opportunity
    • 2.2.4. Challenges
    • 2.2.5. Key Trends
  • 2.3. Macro-Economic Factors
    • 2.3.1. Global Sectorial Outlook
    • 2.3.2. Global GDP Growth Outlook
  • 2.4. COVID-19 Impact Analysis
  • 2.5. Forecast Factors - Relevance and Impact

3. Value Added Insights

  • 3.1. Regulatory Landscape
  • 3.2. Product Adoption Analysis
  • 3.3. Value Chain Analysis
  • 3.4. Key Deals and Mergers
  • 3.5. PESTLE Analysis
  • 3.6. Porter's Five Force Analysis

4. Global Small Molecule CMO/CDMO Market Outlook:

  • 4.1. Key Highlights
    • 4.1.1. Market Size (US$ Bn) and Y-o-Y Growth
    • 4.1.2. Absolute $ Opportunity
  • 4.2. Market Size (US$ Bn) Analysis and Forecast
    • 4.2.1. Historical Market Size (US$ Bn) Analysis, 2019 - 2024
    • 4.2.2. Current Market Size (US$ Bn) Analysis and Forecast, 2025 - 2032
  • 4.3. Global Small Molecule CMO/CDMO Market Outlook: Product
    • 4.3.1. Introduction / Key Findings
    • 4.3.2. Historical Market Size (US$ Bn) Analysis, By Product, 2019 - 2024
    • 4.3.3. Current Market Size (US$ Bn) Analysis and Forecast, By Product, 2025 - 2032
      • 4.3.3.1. Standard API
      • 4.3.3.2. HP API
    • 4.3.4. Market Attractiveness Analysis: Product
  • 4.4. Global Small Molecule CMO/CDMO Market Outlook: Service
    • 4.4.1. Introduction / Key Findings
    • 4.4.2. Historical Market Size (US$ Bn) Analysis, By Service, 2019 - 2024
    • 4.4.3. Current Market Size (US$ Bn) Analysis and Forecast, By Service, 2025 - 2032
      • 4.4.3.1. Process Development
      • 4.4.3.2. Analytical Method Development
      • 4.4.3.3. GMP Manufacturing Service
      • 4.4.3.4. Scale-up and Tech Transfer
      • 4.4.3.5. Regulatory Assistance
      • 4.4.3.6. Fill-Finish Services
    • 4.4.4. Market Attractiveness Analysis: Service
  • 4.5. Global Small Molecule CMO/CDMO Market Outlook: Company Size
    • 4.5.1. Introduction / Key Findings
    • 4.5.2. Historical Market Size (US$ Bn) Analysis, By Company Size, 2019 - 2024
    • 4.5.3. Current Market Size (US$ Bn) Analysis and Forecast, By Company Size, 2025 - 2032
      • 4.5.3.1. Small
      • 4.5.3.2. Mid-sized
      • 4.5.3.3. Large
    • 4.5.4. Market Attractiveness Analysis: Company Size
  • 4.6. Global Small Molecule CMO/CDMO Market Outlook: Scale of Operation
    • 4.6.1. Introduction / Key Findings
    • 4.6.2. Historical Market Size (US$ Bn) Analysis, By Scale of Operation, 2019 - 2024
    • 4.6.3. Current Market Size (US$ Bn) Analysis and Forecast, By Scale of Operation, 2025 - 2032
      • 4.6.3.1. Clinical
      • 4.6.3.2. Commercial
    • 4.6.4. Market Attractiveness Analysis: Scale of Operation

5. Global Small Molecule CMO/CDMO Market Outlook: Region

  • 5.1. Key Highlights
  • 5.2. Historical Market Size (US$ Bn) Analysis, By Region, 2019 - 2024
  • 5.3. Current Market Size (US$ Bn) Analysis and Forecast, By Region, 2025 - 2032
    • 5.3.1. North America
    • 5.3.2. Europe
    • 5.3.3. East Asia
    • 5.3.4. South Asia and Oceania
    • 5.3.5. Latin America
    • 5.3.6. Middle East & Africa
  • 5.4. Market Attractiveness Analysis: Region

6. North America Small Molecule CMO/CDMO Market Outlook:

  • 6.1. Key Highlights
  • 6.2. Historical Market Size (US$ Bn) Analysis, By Market, 2019 - 2024
    • 6.2.1. By Country
    • 6.2.2. By Product
    • 6.2.3. By Service
    • 6.2.4. By Company Size
    • 6.2.5. By Scale of Operation
  • 6.3. Current Market Size (US$ Bn) Analysis and Forecast, By Country, 2025 - 2032
    • 6.3.1. U.S.
    • 6.3.2. Canada
  • 6.4. Current Market Size (US$ Bn) Analysis and Forecast, By Product, 2025 - 2032
    • 6.4.1. Standard API
    • 6.4.2. HP API
  • 6.5. Current Market Size (US$ Bn) Analysis and Forecast, By Service, 2025 - 2032
    • 6.5.1. Process Development
    • 6.5.2. Analytical Method Development
    • 6.5.3. GMP Manufacturing Service
    • 6.5.4. Scale-up and Tech Transfer
    • 6.5.5. Regulatory Assistance
    • 6.5.6. Fill-Finish Services
  • 6.6. Current Market Size (US$ Bn) Analysis and Forecast, By Company Size, 2025 - 2032
    • 6.6.1. Small
    • 6.6.2. Mid-sized
    • 6.6.3. Large
  • 6.7. Current Market Size (US$ Bn) Analysis and Forecast, By Scale of Operation, 2025 - 2032
    • 6.7.1. Clinical
    • 6.7.2. Commercial
  • 6.8. Market Attractiveness Analysis

7. Europe Small Molecule CMO/CDMO Market Outlook:

  • 7.1. Key Highlights
  • 7.2. Historical Market Size (US$ Bn) Analysis, By Market, 2019 - 2024
    • 7.2.1. By Country
    • 7.2.2. By Product
    • 7.2.3. By Service
    • 7.2.4. By Company Size
    • 7.2.5. By Scale of Operation
  • 7.3. Current Market Size (US$ Bn) Analysis and Forecast, By Country, 2025 - 2032
    • 7.3.1. Germany
    • 7.3.2. France
    • 7.3.3. U.K.
    • 7.3.4. Italy
    • 7.3.5. Spain
    • 7.3.6. Russia
    • 7.3.7. Turkey
    • 7.3.8. Rest of Europe
  • 7.4. Current Market Size (US$ Bn) Analysis and Forecast, By Product, 2025 - 2032
    • 7.4.1. Standard API
    • 7.4.2. HP API
  • 7.5. Current Market Size (US$ Bn) Analysis and Forecast, By Service, 2025 - 2032
    • 7.5.1. Process Development
    • 7.5.2. Analytical Method Development
    • 7.5.3. GMP Manufacturing Service
    • 7.5.4. Scale-up and Tech Transfer
    • 7.5.5. Regulatory Assistance
    • 7.5.6. Fill-Finish Services
  • 7.6. Current Market Size (US$ Bn) Analysis and Forecast, By Company Size, 2025 - 2032
    • 7.6.1. Small
    • 7.6.2. Mid-sized
    • 7.6.3. Large
  • 7.7. Current Market Size (US$ Bn) Analysis and Forecast, By Scale of Operation, 2025 - 2032
    • 7.7.1. Clinical
    • 7.7.2. Commercial
  • 7.8. Market Attractiveness Analysis

8. East Asia Small Molecule CMO/CDMO Market Outlook:

  • 8.1. Key Highlights
  • 8.2. Historical Market Size (US$ Bn) Analysis, By Market, 2019 - 2024
    • 8.2.1. By Country
    • 8.2.2. By Product
    • 8.2.3. By Service
    • 8.2.4. By Company Size
    • 8.2.5. By Scale of Operation
  • 8.3. Current Market Size (US$ Bn) Analysis and Forecast, By Country, 2025 - 2032
    • 8.3.1. China
    • 8.3.2. Japan
    • 8.3.3. South Korea
  • 8.4. Current Market Size (US$ Bn) Analysis and Forecast, By Product, 2025 - 2032
    • 8.4.1. Standard API
    • 8.4.2. HP API
  • 8.5. Current Market Size (US$ Bn) Analysis and Forecast, By Service, 2025 - 2032
    • 8.5.1. Process Development
    • 8.5.2. Analytical Method Development
    • 8.5.3. GMP Manufacturing Service
    • 8.5.4. Scale-up and Tech Transfer
    • 8.5.5. Regulatory Assistance
    • 8.5.6. Fill-Finish Services
  • 8.6. Current Market Size (US$ Bn) Analysis and Forecast, By Company Size, 2025 - 2032
    • 8.6.1. Small
    • 8.6.2. Mid-sized
    • 8.6.3. Large
  • 8.7. Current Market Size (US$ Bn) Analysis and Forecast, By Scale of Operation, 2025 - 2032
    • 8.7.1. Clinical
    • 8.7.2. Commercial
  • 8.8. Market Attractiveness Analysis

9. South Asia & Oceania Small Molecule CMO/CDMO Market Outlook:

  • 9.1. Key Highlights
  • 9.2. Historical Market Size (US$ Bn) Analysis, By Market, 2019 - 2024
    • 9.2.1. By Country
    • 9.2.2. By Product
    • 9.2.3. By Service
    • 9.2.4. By Company Size
    • 9.2.5. By Scale of Operation
  • 9.3. Current Market Size (US$ Bn) Analysis and Forecast, By Country, 2025 - 2032
    • 9.3.1. India
    • 9.3.2. Southeast Asia
    • 9.3.3. ANZ
    • 9.3.4. Rest of South Asia & Oceania
  • 9.4. Current Market Size (US$ Bn) Analysis and Forecast, By Product, 2025 - 2032
    • 9.4.1. Standard API
    • 9.4.2. HP API
  • 9.5. Current Market Size (US$ Bn) Analysis and Forecast, By Service, 2025 - 2032
    • 9.5.1. Process Development
    • 9.5.2. Analytical Method Development
    • 9.5.3. GMP Manufacturing Service
    • 9.5.4. Scale-up and Tech Transfer
    • 9.5.5. Regulatory Assistance
    • 9.5.6. Fill-Finish Services
  • 9.6. Current Market Size (US$ Bn) Analysis and Forecast, By Company Size, 2025 - 2032
    • 9.6.1. Small
    • 9.6.2. Mid-sized
    • 9.6.3. Large
  • 9.7. Current Market Size (US$ Bn) Analysis and Forecast, By Scale of Operation, 2025 - 2032
    • 9.7.1. Clinical
    • 9.7.2. Commercial
  • 9.8. Market Attractiveness Analysis

10. Latin America Small Molecule CMO/CDMO Market Outlook:

  • 10.1. Key Highlights
  • 10.2. Historical Market Size (US$ Bn) Analysis, By Market, 2019 - 2024
    • 10.2.1. By Country
    • 10.2.2. By Product
    • 10.2.3. By Service
    • 10.2.4. By Company Size
    • 10.2.5. By Scale of Operation
  • 10.3. Current Market Size (US$ Bn) Analysis and Forecast, By Country, 2025 - 2032
    • 10.3.1. Brazil
    • 10.3.2. Mexico
    • 10.3.3. Rest of Latin America
  • 10.4. Current Market Size (US$ Bn) Analysis and Forecast, By Product, 2025 - 2032
    • 10.4.1. Standard API
    • 10.4.2. HP API
  • 10.5. Current Market Size (US$ Bn) Analysis and Forecast, By Service, 2025 - 2032
    • 10.5.1. Process Development
    • 10.5.2. Analytical Method Development
    • 10.5.3. GMP Manufacturing Service
    • 10.5.4. Scale-up and Tech Transfer
    • 10.5.5. Regulatory Assistance
    • 10.5.6. Fill-Finish Services
  • 10.6. Current Market Size (US$ Bn) Analysis and Forecast, By Company Size, 2025 - 2032
    • 10.6.1. Small
    • 10.6.2. Mid-sized
    • 10.6.3. Large
  • 10.7. Current Market Size (US$ Bn) Analysis and Forecast, By Scale of Operation, 2025 - 2032
    • 10.7.1. Clinical
    • 10.7.2. Commercial
  • 10.8. Market Attractiveness Analysis

11. Middle East & Africa Small Molecule CMO/CDMO Market Outlook:

  • 11.1. Key Highlights
  • 11.2. Historical Market Size (US$ Bn) Analysis, By Market, 2019 - 2024
    • 11.2.1. By Country
    • 11.2.2. By Product
    • 11.2.3. By Service
    • 11.2.4. By Company Size
    • 11.2.5. By Scale of Operation
  • 11.3. Current Market Size (US$ Bn) Analysis and Forecast, By Country, 2025 - 2032
    • 11.3.1. GCC Countries
    • 11.3.2. Egypt
    • 11.3.3. South Africa
    • 11.3.4. Northern Africa
    • 11.3.5. Rest of Middle East & Africa
  • 11.4. Current Market Size (US$ Bn) Analysis and Forecast, By Product, 2025 - 2032
    • 11.4.1. Standard API
    • 11.4.2. HP API
  • 11.5. Current Market Size (US$ Bn) Analysis and Forecast, By Service, 2025 - 2032
    • 11.5.1. Process Development
    • 11.5.2. Analytical Method Development
    • 11.5.3. GMP Manufacturing Service
    • 11.5.4. Scale-up and Tech Transfer
    • 11.5.5. Regulatory Assistance
    • 11.5.6. Fill-Finish Services
  • 11.6. Current Market Size (US$ Bn) Analysis and Forecast, By Company Size, 2025 - 2032
    • 11.6.1. Small
    • 11.6.2. Mid-sized
    • 11.6.3. Large
  • 11.7. Current Market Size (US$ Bn) Analysis and Forecast, By Scale of Operation, 2025 - 2032
    • 11.7.1. Clinical
    • 11.7.2. Commercial
  • 11.8. Market Attractiveness Analysis

12. Competition Landscape

  • 12.1. Market Share Analysis, 2024
  • 12.2. Market Structure
    • 12.2.1. Competition Intensity Mapping By Market
    • 12.2.2. Competition Dashboard
  • 12.3. Company Profiles (Details - Overview, Financials, Strategy, Recent Developments)
    • 12.3.1. Lonza
      • 12.3.1.1. Overview
      • 12.3.1.2. Segments and Products
      • 12.3.1.3. Key Financials
      • 12.3.1.4. Market Developments
      • 12.3.1.5. Market Strategy
    • 12.3.2. Pfizer CentreOne (Pfizer Inc.)
    • 12.3.3. Piramal Pharma Solutions
    • 12.3.4. Wuxi App Tec
    • 12.3.5. Patheon (Thermo Fisher Scientific Inc.)
    • 12.3.6. Ajinomoto Bio-Pharma Solutions
    • 12.3.7. Siegfried Holding AG
    • 12.3.8. Eurofins Scientific
    • 12.3.9. Aurigene Pharmaceutical Services Ltd.
    • 12.3.10. Asymchema
    • 12.3.11. PCI Pharma Services
    • 12.3.12. Almac Group
    • 12.3.13. Labcorp Drug Development
    • 12.3.14. Sumitomo Chemical Co., Ltd.
    • 12.3.15. ICROM
    • 12.3.16. AGC Inc.
    • 12.3.17. FUJIFILM Corporation
    • 12.3.18. CMIC HOLDINGS Co., LTD.
    • 12.3.19. Evonik
    • 12.3.20. Terumo Pharmaceutical Solutions (TPS)

13. Appendix

  • 13.1. Research Methodology
  • 13.2. Research Assumptions
  • 13.3. Acronyms and Abbreviations